(Total Views: 592)
Posted On: 06/04/2019 10:28:59 AM
Post# of 30035
ADMS offers a cautionary tale to anyone that picks up and commercializes Elto for PLID. Why they chose a WAC of $130k a year for an old ER version of Amantadine is one of the reasons they are failing.
Especially in this day of drug price sensitivity. If Elto makes it to market for PLID they can take 100% of ADMS market share by pricing at $20k a year.
The VP of Managed Markets who made the pricing decision will likely be fired.
Especially in this day of drug price sensitivity. If Elto makes it to market for PLID they can take 100% of ADMS market share by pricing at $20k a year.
The VP of Managed Markets who made the pricing decision will likely be fired.
(4)
(0)Scroll down for more posts ▼
